Skip to content
ppharmaranks
Menu

Hematopoietic Stem Cell Mobilizer drugs compared

Compare all 1 Hematopoietic Stem Cell Mobilizer drug side by side, used for conditions such as lymphoma, non-hodgkin, multiple myeloma. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.

1 of 1 drug in this class carry a pharmaranks safety score, ranging 72–72 out of 100 — computed from FDA recall records, not from reviews.

Rated against independent sources·Last updated June 7, 2026·How we rate

Full ranking · 1 drugs

  1. 1

    mozobil

    Plerixafor

    72/100

Frequently asked questions

What is the Hematopoietic Stem Cell Mobilizer drug class?

Hematopoietic Stem Cell Mobilizer is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 1 Hematopoietic Stem Cell Mobilizer product, each independently rated.

Are all Hematopoietic Stem Cell Mobilizer drugs the same?

No. Hematopoietic Stem Cell Mobilizer drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Hematopoietic Stem Cell Mobilizer drugs treat?

Per NIH RxClass drug-classification data, Hematopoietic Stem Cell Mobilizer drugs are used for conditions including lymphoma, non-hodgkin, multiple myeloma.

Sources: the Hematopoietic Stem Cell Mobilizer class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.